LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is a Legend Biotech Corp program in relapsed/refractory B-cell non-Hodgkin lymphoma. Its next catalyst is a Readout on Dec 13, 2026.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Relapsed/refractory B-cell non-Hodgkin lymphoma. Sponsor: Legend Biotech Corp (LEGN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is a Readout on Dec 13, 2026.
No FDA decision for LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is in our archive yet.
In our records LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) is under review or in development for Relapsed/refractory B-cell non-Hodgkin lymphoma.
Legend Biotech Corp (LEGN).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.